Gufic Biosciences Limited (GUFICBIO.BO)
INR 317.25
(2.11%)
INR 317.25
(2.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.07 Billion INR | -34.56% |
| 2022 | 2.46 Billion INR | 3.5% |
| 2021 | 2.38 Billion INR | 47.17% |
| 2020 | 1.61 Billion INR | 6.27% |
| 2019 | 1.52 Billion INR | 19.96% |
| 2018 | 1.26 Billion INR | 1.02% |
| 2017 | 1.25 Billion INR | 21.87% |
| 2016 | 1.03 Billion INR | 26.95% |
| 2015 | 811.99 Million INR | 40.11% |
| 2014 | 579.55 Million INR | 26.43% |
| 2013 | 458.41 Million INR | 17.64% |
| 2012 | 389.66 Million INR | 21.33% |
| 2011 | 321.16 Million INR | 5.61% |
| 2010 | 304.11 Million INR | 21.99% |
| 2009 | 249.28 Million INR | 29.05% |
| 2008 | 193.17 Million INR | 12.37% |
| 2007 | 171.91 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 432.47 Million INR | 9.81% |
| 2023 Q3 | 741.29 Million INR | 4.85% |
| 2023 Q4 | 393.84 Million INR | -46.87% |
| 2023 FY | 1.61 Billion INR | -34.56% |
| 2023 Q2 | 706.97 Million INR | 5.61% |
| 2023 Q1 | 669.39 Million INR | 5.23% |
| 2022 FY | 2.46 Billion INR | 3.5% |
| 2022 Q3 | 624.82 Million INR | 1.76% |
| 2022 Q4 | 636.14 Million INR | 1.81% |
| 2022 Q1 | 589.3 Million INR | 28.69% |
| 2022 Q2 | 614.02 Million INR | 4.19% |
| 2021 Q3 | 559.79 Million INR | -2.89% |
| 2021 Q4 | 457.91 Million INR | -18.2% |
| 2021 Q1 | 614.63 Million INR | 3.5% |
| 2021 FY | 2.38 Billion INR | 47.17% |
| 2021 Q2 | 576.45 Million INR | -6.21% |
| 2020 FY | 1.61 Billion INR | 6.27% |
| 2020 Q4 | 593.84 Million INR | 21.95% |
| 2020 Q3 | 486.96 Million INR | 16.35% |
| 2020 Q2 | 418.52 Million INR | 30.93% |
| 2020 Q1 | 319.64 Million INR | 10.71% |
| 2019 Q4 | 288.7 Million INR | -27.71% |
| 2019 Q3 | 399.35 Million INR | 22.35% |
| 2019 Q2 | 326.4 Million INR | -14.53% |
| 2019 Q1 | 381.89 Million INR | 11.23% |
| 2019 FY | 1.52 Billion INR | 19.96% |
| 2018 Q3 | 323.28 Million INR | 13.72% |
| 2018 FY | 1.26 Billion INR | 1.02% |
| 2018 Q4 | 343.34 Million INR | 6.21% |
| 2018 Q2 | 284.27 Million INR | -21.22% |
| 2018 Q1 | 360.82 Million INR | 5.74% |
| 2017 Q1 | 251.49 Million INR | -7.58% |
| 2017 FY | 1.25 Billion INR | 21.87% |
| 2017 Q3 | 337.64 Million INR | 12.81% |
| 2017 Q4 | 341.23 Million INR | 1.06% |
| 2017 Q2 | 299.31 Million INR | 19.01% |
| 2016 FY | 1.03 Billion INR | 26.95% |
| 2016 Q2 | 259.82 Million INR | 8.21% |
| 2016 Q1 | 240.11 Million INR | 28.47% |
| 2016 Q4 | 272.13 Million INR | -3.68% |
| 2016 Q3 | 282.51 Million INR | 8.73% |
| 2015 Q1 | 185.28 Million INR | 31.94% |
| 2015 Q2 | 217.04 Million INR | 17.14% |
| 2015 Q3 | 222.83 Million INR | 2.67% |
| 2015 FY | 811.99 Million INR | 40.11% |
| 2015 Q4 | 186.9 Million INR | -16.13% |
| 2014 Q3 | 150.55 Million INR | 3.41% |
| 2014 Q4 | 140.43 Million INR | -6.73% |
| 2014 Q2 | 145.58 Million INR | 2.92% |
| 2014 Q1 | 141.46 Million INR | 20.83% |
| 2014 FY | 579.55 Million INR | 26.43% |
| 2013 Q2 | 95.33 Million INR | -3.13% |
| 2013 Q4 | 117.07 Million INR | -20.68% |
| 2013 FY | 458.41 Million INR | 17.64% |
| 2013 Q3 | 147.6 Million INR | 54.83% |
| 2013 Q1 | 98.4 Million INR | 30.46% |
| 2012 FY | 389.66 Million INR | 21.33% |
| 2012 Q1 | 95.42 Million INR | -3.72% |
| 2012 Q4 | 75.43 Million INR | -22.77% |
| 2012 Q3 | 97.66 Million INR | -17.54% |
| 2012 Q2 | 118.44 Million INR | 24.12% |
| 2011 Q3 | 81.18 Million INR | 0.0% |
| 2011 FY | 321.16 Million INR | 5.61% |
| 2011 Q4 | 99.11 Million INR | 22.09% |
| 2010 FY | 304.11 Million INR | 21.99% |
| 2009 FY | 249.28 Million INR | 29.05% |
| 2008 FY | 193.17 Million INR | 12.37% |
| 2007 FY | 171.91 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 93.209% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 97.253% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 90.742% |
| Granules India Limited | 7.18 Billion INR | 84.995% |
| Indoco Remedies Limited | 4.74 Billion INR | 77.305% |
| Achyut Healthcare Limited | 1.6 Million INR | -66880.174% |
| Ajanta Pharma Limited | 30.46 Billion INR | 96.462% |
| Alkem Laboratories Limited | 32.83 Billion INR | 96.718% |
| Alpa Laboratories Limited | 156.14 Million INR | -590.19% |
| Brooks Laboratories Limited | 51.18 Million INR | -2005.727% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 58.556% |
| Bajaj HealthCare Limited | 985.34 Million INR | -9.374% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 24.063% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 98.876% |
| Eris Lifesciences Limited | 4.94 Billion INR | 78.197% |
| FDC Limited | 5.34 Billion INR | 79.85% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.405% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 49.265% |
| Ipca Laboratories Limited | 13.91 Billion INR | 92.255% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -39.345% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -2234.932% |
| Lasa Supergenerics Limited | 291.17 Million INR | -270.126% |
| Laurus Labs Limited | 3.01 Billion INR | 64.205% |
| Lupin Limited | 95.67 Billion INR | 98.874% |
| Mankind Pharma Limited | 23.15 Billion INR | 95.345% |
| Medicamen Biotech Limited | 335.16 Million INR | -221.544% |
| Medico Remedies Limited | 161.84 Million INR | -565.895% |
| Megasoft Limited | 49.52 Million INR | -2075.963% |
| NATCO Pharma Limited | 10.05 Billion INR | 89.285% |
| Piramal Pharma Limited | 19.91 Billion INR | 94.588% |
| RPG Life Sciences Limited | 1.63 Billion INR | 34.105% |
| Sigachi Industries Limited | 579.88 Million INR | -85.848% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.301% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 23.174% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -14.358% |
| Unichem Laboratories Limited | 6.72 Billion INR | 83.977% |
| Wanbury Limited | 1.16 Billion INR | 7.168% |
| Windlas Biotech Limited | 1 Billion INR | -7.074% |
| ZIM Laboratories Limited | 1.01 Billion INR | -6.382% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 97.504% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 64.973% |
| Divi's Laboratories Limited | 14.17 Billion INR | 92.394% |
| Hester Biosciences Limited | 908.84 Million INR | -18.581% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 64.021% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | 1.936% |
| Bal Pharma Limited | 389.89 Million INR | -176.414% |
| Strides Pharma Science Limited | 9.16 Billion INR | 88.238% |
| Venus Remedies Limited | 1.91 Billion INR | 43.76% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 64.946% |
| Nectar Lifesciences Limited | 625.55 Million INR | -72.282% |
| Shilpa Medicare Limited | 2.18 Billion INR | 50.577% |
| Aarti Drugs Limited | 1.16 Billion INR | 7.689% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 1.919% |
| Suven Life Sciences Limited | 109.75 Million INR | -881.969% |
| Ind-Swift Limited | 946.56 Million INR | -13.855% |
| Valiant Laboratories Limited | 36.28 Million INR | -2869.801% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 87.196% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 76.468% |
| Themis Medicare Limited | 782.85 Million INR | -37.664% |
| Hikal Limited | 2.48 Billion INR | 56.655% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 94.969% |
| Sequent Scientific Limited | 2.9 Billion INR | 62.861% |
| Novartis India Limited | 470.1 Million INR | -129.251% |
| Wockhardt Limited | 6.4 Billion INR | 83.161% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 92.544% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -6548.557% |
| Neuland Laboratories Limited | 2.92 Billion INR | 63.215% |
| Morepen Laboratories Limited | 1.98 Billion INR | 45.774% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -161.31% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -59.39% |